Ohr Pharmaceutical, Inc. that it has entered into a definitive merger agreement with NeuBase Therapeutics, Inc. ("NeuBase"), under which the stockholders of NeuBase would become the majority holders of the combined company. The proposed merger will create a public company focused on advancing NeuBase's peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL(TM)) technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. Upon closing of the transaction, the combined company will change its name to NeuBase Therapeutics, Inc. and propose its trading symbol on the NASDAQ be changed to NBSE. The executive team of NeuBase will serve as the executive team of the combined company, led by Dietrich A. Stephan, Ph.D. as Chief Executive Officer.